Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

ur Phase II trial testing bavituximab and docetaxel in advanced breast cancer patients. Our anti-viral program received global attention with a publication in the leading journal Nature Medicine highlighting the broad anti-viral potential of bavituximab and other anti-PS antibodies, and we were also awarded a broad U.S. patent covering anti-viral applications of antibodies that directly target PS. These developments, following a major government contract award last quarter to study bavituximab in viral hemorrhagic fever infections, have established our PS-targeting anti-viral platform as an approach that could represent a completely new class of drugs for the treatment of life-threatening viral infections. We look forward to reporting continued progress in our anti-PS programs in the coming months, as well as providing an update on progress in our Cotara(R) clinical program."

Mr. King continued, "Our Avid manufacturing subsidiary continued to expand its client base during the quarter and increased its manufacturing capacity with the addition of an innovative single-use bioreactor system, which should allow Avid to meet the growing demand for its cell culture production services using state-of-the-art, cost-effective technology. Avid revenues recorded this quarter were lower than last year's as a result of the timing of shipments of finished product to customers, but based on product now being readied for shipping and our backlog of orders in hand, we expect robust revenue growth from Avid over the remainder of the fiscal year, with revenues in the third quarter of FY 2009 estimated at upwards of $5 million."

Mr. King concluded, "Despite the turmoil in the global financial markets, we have never been more optimistic about the potential of our lead drug candidates. The encouraging progress in our clinical programs to date and increasing scientific recognition of the promise of our innovative technology have already
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... The ... Pain and Obesity ”. , As corresponding author Professor Akiko Okifuji says “Both obesity ... often, although it is not to say that one causes the other. Rather, there ...
(Date:8/4/2015)... ... 2015 , ... Exsurco Medical, Inc. is proud ... as an Affiliate Member. Exsurco Medical finds this an exciting opportunity to ... lives by promoting the safety, quality and availability of donated tissue for transplantation, ...
(Date:8/4/2015)... ... 2015 , ... The United Nations Foundation today announced a ... for a select group of U.S.-based journalists during the week of November 9, ... International Conference on Family Planning in Bali. , In close coordination with ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... formula. Healthy Origins® Cognizin® is a trademark for Citicoline, a nutrient that ... a capsule for those applications which have more of a semi-solid composition. ...
(Date:8/4/2015)... ... 2015 , ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp ... hats that have a flip-up face shield. The sleek contours of the new ... to remove their headlamp when raising or lowering their face shield or visor. The ...
Breaking Medicine News(10 mins):Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3
... in Wonderland was well advised to stay asleep especially as ... in the tea-time conversation. Dormice in Europe spend about eight ... extended period, with almost all of them surviving the winter. ... Austria, the Czech Republic, England, Germany and Italy. Karin Lebl ...
... close attention to how the United Kingdom carries out plans ... beyond clinical and cost effectiveness, according to researchers at the ... to appear in the April 7 issue of the ... discuss a new, "value-based pricing" policy proposed by the British ...
... -- Having a good laugh on April Fool,s Day or ... benefits your blood vessels, an expert says. "Laughter increases ... stress is especially beneficial for persons who have hypertension [high ... Vascular Surgery news release. April is National Stress Awareness ...
... a unique system to perform in vivo RNAi ... that regulate hepatocyte proliferation during chronic liver damage.1 ... stable knockdown of the candidate gene by different ... mouse hepatocytes and also increase the regenerative capacity ...
... 1 issue of the journal SLEEP demonstrates that an ... sleep disturbances, as well as providing positive, indirect benefits ... that the Internet can give parents widespread access to ... children. Results show that there were significant improvements ...
... Researchers have found that it may not be necessary to ... analyzing non-tumor tissue may be an effective option, according to ... of the American Association for Cancer Research. "A ... detect the presence of tumor," said lead researcher Dan Mercola, ...
Cached Medicine News:Health News:Sleeping through danger: the dormouse approach to survival 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3Health News:Internet program reduces infant and toddler sleep problems, helps moms sleep better too 2Health News:Internet program reduces infant and toddler sleep problems, helps moms sleep better too 3Health News:New tool allows for an alternate method of prostate cancer diagnosis 2
(Date:8/4/2015)... N.J. and LOS ANGELES ... Diagnostics (NYSE: DGX ), the world,s leading ... it has completed the previously announced acquisition of ... As a result of the transaction, ... extensive range of innovative services and network of ...
(Date:8/4/2015)... 2015  Sutro Biopharma today announced that it ... vice president of alliance and project management. Dr. ... management of Sutro,s collaborative partnerships and the development ... bispecific antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... years of experience in the biopharmaceutical sector with ...
(Date:8/4/2015)... 4, 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... summarizing data from studies in Europe ... Hepatic CHEMOSAT ® Delivery System (CHEMOSAT) will be presented ... congress, which will be held in Marseille, ...
Breaking Medicine Technology:Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
... Inc., a neurology-focused specialty pharmaceutical company, announced today that ... of CAMBIA™ (diclofenac potassium for oral solution) will be ... Neurology Conference (CONy) in Barcelona, Spain. The ... entitled, "Rapid and Sustained Improvement in Migraine Symptoms with ...
... joint guideline by the American Society of Hematology (ASH) ... physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), ... to produce more red blood cells, to treat cancer ... ESAs are associated with shorter survival and increased risk ...
Cached Medicine Technology:New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 2New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 3New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 4New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 2New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 3
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
Medicine Products: